TL;DR
At Aarise Pharma, we explain that USP-grade hormone API verification rests on the current batch, applicable monograph, suitable methods, and documented results, not a generic supplier or GMP claim. We show formulation teams how to check a COA, manufacturing site, regulatory documents, reference standards, change control, and out-of-specification handling before purchase.
Formulation teams cannot authenticate an API grade from a supplier catalog alone. In a published USP monograph, the lower assay limit for levothyroxine sodium is 97.0%, which shows why the exact form and calculation basis matter.
A hormone API is supportably described as USP-grade only when the current batch is tested against the applicable USP monograph using suitable methods and meets every required specification. Supplier claims, GMP certificates, and generic COAs are not substitutes. Formulation companies should verify monograph applicability, method references, impurity results, manufacturing site, change control, and supporting regulatory documents.
We explain the evidence to request, how to read it, and how to compare a claimed supply option before approving material for formulation work.
How Does USP-Grade Hormone API Verification Work?
USP-Grade Hormone API Verification starts with a simple principle: a grade claim belongs to a specific material and batch, not merely to a supplier or facility. We recommend documenting the exact molecule, ester or salt, hydrate state, intended dosage route, target market, and applicable monograph before requesting a quotation.
Start with the Exact Material
“Estradiol,” “levothyroxine,” and a hormone ester are not interchangeable labels. We match the purchase specification to the chemical name, CAS number, physical form, assay basis, and relevant compendial article. This reduces the risk of evaluating a COA against the wrong requirement.
For broader sourcing context, our Hormone Sourcing Guide helps teams frame product, market, and documentation requirements before supplier qualification begins.
Require Batch-Level Evidence
FDA explains that each batch of a compendial API must meet applicable monograph acceptance criteria, while an alternative test method must be fully validated, suitable, and equivalent or better than the official procedure. That is why we ask for a current COA with numerical results, not a generic compliance statement. FDA guidance
Separate Claims from Proof
A supplier may accurately describe its facility as GMP compliant and its portfolio as USP capable. Neither statement proves the current lot conforms. We treat the monograph reference, analytical method, raw data availability, manufacturing site, and batch release decision as separate evidence points.
How Do You Match a Hormone API to the Correct USP Monograph?
A name match is only the first check. We confirm whether the compendial article covers the precise free base, salt, ester, hydrate, or other defined form being purchased, then record the edition or online revision reviewed. USP notes that some monograph definition text is informational rather than a requirement, so buyers should identify the actual tests and acceptance criteria. USP notices
Confirm the Form and Calculation Basis
For progesterone, estradiol, and levothyroxine sodium, the supplier specification must match the named article and its stated calculation basis. A correct assay value on an anhydrous basis can be misleading if the purchased material is specified on a different basis.
Record the Evidence Version
We record the monograph title, edition or revision, official status, test-method reference, and date checked. This creates an auditable trail when a monograph, customer specification, or regulatory filing changes.
Check the Method and Standard
The COA should identify the method version, and the supplier should be able to explain reference-standard source, system suitability, and method verification. Our Buyer’s Guide offers useful context for structuring those questions across hormone supply decisions.
What Should a Batch COA Show Before Release?
A credible COA makes a batch review possible without forcing the buyer to infer what was tested. ICH Q7 says authentic API COAs should list tests performed, acceptance limits, numerical results, batch information, release information, and original manufacturer details where relevant. ICH Q7
Verify Identity and Traceability
Look for the exact API name, form, batch number, manufacturing date, release date, retest or expiry date, manufacturer identity, and analytical-laboratory identity. A repacker-issued document should still identify the original manufacturer and original batch certificate.
Read Assay and Identification Results
A useful COA shows the specification and numerical result, including the stated basis of calculation. For identity, ask whether every required procedure was completed and whether the method reference corresponds to the applicable article or validated alternative.
Review Impurities and Solvents
Assess individual and total related substances, unknown impurities, residual solvents, water or loss on drying, and any physical attribute that matters to the dosage form. Our COA Checklist helps quality teams turn those fields into a repeatable review process.
Ask About OOS and Change History
Any out-of-specification result should be investigated and documented. We ask suppliers how they handle invalid results, retesting, resampling, CAPA, and changes to raw materials, methods, equipment, process steps, or manufacturing sites before accepting a replacement batch.
Why Are GMP and USP Conformance Different?
GMP describes the manufacturing quality system. USP conformance describes whether a specific material meets defined tests, methods, and acceptance criteria. Both matter, but they answer different questions, which is why a current GMP certificate cannot replace a batch COA and monograph assessment.
| Question | GMP Evidence Answers | USP Conformance Evidence Answers |
|---|---|---|
| What Is Being Assessed? | Manufacturing controls, records, deviations, training, and quality oversight | Identity, assay, impurities, and other applicable acceptance criteria |
| What Evidence Is Needed? | Current certificate, site scope, audit evidence, and quality-system controls | Batch COA, monograph mapping, method reference, and numerical results |
| Can It Prove The Other? | No, GMP does not prove a batch meets every compendial requirement | No, a passing batch result does not prove the site has an adequate GMP system |
| What Happens After An OOS Result? | Investigation, documented retesting rules, CAPA, and quality review | The batch needs resolved evidence before it can support a conformance claim |
ICH defines a specification as tests, analytical procedures, and acceptance criteria, while placing specifications within a wider quality system that also includes GMP and process controls. ICH Q6A
A CEP is also not a substitute for USP evidence. It addresses suitability to European Pharmacopoeia monographs, so buyers should review its scope and confirm the correct standard for their intended market. Our GMP Export Guide explains why site qualification and compendial review should run in parallel.
How Should Formulation Companies Verify a Supplier Before Purchase?
Supplier selection should be evidence-led. On our public page, we describe hormone API availability and documentation categories we may discuss with buyers, but each molecule and batch still needs its own review before a buyer can substantiate a USP-grade claim.
| Molecule | Supplier | Claimed Grade | Monograph Check | Claimed Site | COA Availability | Claimed Regulatory Documents | Last Public Review |
|---|---|---|---|---|---|---|---|
| Testosterone Enanthate | Aarise Pharma | USP, BP, IP | Confirm article and ester for target market | Haridwar, India | Batch COA claimed with order, no public sample | COA, MSDS, DMF support, COPP | 17 Sep 2026 |
| Progesterone | Aarise Pharma | USP, BP, IP | Match to USP Progesterone requirements | Haridwar, India | Batch COA claimed with order, no public sample | COA, MSDS, DMF support, COPP | 17 Sep 2026 |
| Estradiol | Aarise Pharma | USP, BP, IP | Confirm exact estradiol form | Haridwar, India | Batch COA claimed with order, no public sample | COA, MSDS, DMF support, COPP | 17 Sep 2026 |
| Levothyroxine Sodium | Aarise Pharma | USP, BP, IP | Confirm sodium salt, hydrate state, and assay basis | Haridwar, India | Batch COA claimed with order, no public sample | COA, MSDS, DMF support, COPP | 17 Sep 2026 |
| Insulin Glargine | Aarise Pharma | USP, BP, IP | Confirm applicable compendial and biologic controls | Haridwar, India | Batch COA claimed with order, no public sample | COA, MSDS, DMF support, COPP | 17 Sep 2026 |
Before a commercial decision, our Testing Guide helps teams align analytical questions with the fields that matter to the intended dosage form.
Follow a Five-Step Verification Workflow
- Define the exact molecule, form, dosage route, target market, and applicable monograph.
- Request a current batch COA with tests, limits, numerical results, release date, and manufacturer identity.
- Review method references, reference-standard traceability, impurity profile, residual-solvent controls, and relevant physical attributes.
- Confirm manufacturing-site identity, GMP scope, original-manufacturer traceability, and change-notification commitments.
- Confirm product-specific DMF, Letter of Authorization, CEP, stability, and customer-document availability where applicable.
A DMF is not an approval certificate. FDA reviews it only when an authorized party references it in a relevant application, which makes product coverage and Letter of Authorization availability essential questions. Use our Supplier Overview to build the comparison file before you select a source.
Why Choose Aarise Pharma for Hormone API Verification?
At Aarise Pharma, we believe an API conversation should begin with evidence, not a generic grade label. Our team can help formulation companies define the exact molecule, form, intended market, and document package needed before they qualify material. We will discuss available batch documentation, manufacturing-site traceability, analytical-method references, impurity controls, and the regulatory support relevant to a particular purchase. We also encourage buyers to compare a proposed COA with their written specification and ask early about change notification, retest dating, and access to technical files. That process makes qualification clearer for both quality and procurement teams, whether the need is a development sample or commercial supply. Send us the molecule, form, target market, and intended dosage route, and we will help frame the right evidence request. Where a request cannot be supported, we will identify the gap so your team can decide before ordering. Contact Aarise Pharma.
FAQs on USP-Grade Hormone API Verification
We hear these questions from teams comparing hormone API documentation and supply options. Our Regulated-Market Options can also help buyers frame market-specific qualification questions.
Can a GMP Certificate Prove USP Conformance?
No. A GMP certificate supports the manufacturing quality system, but only current batch evidence against the applicable monograph can substantiate USP conformance for a material.
Can a Supplier Use an Alternative Test Method?
Yes, if the alternative procedure is fully validated, suitable for its intended use, and delivers results equivalent to or better than the official compendial method.
What Documents Support a DMF-Backed Purchase?
Request the applicable DMF reference details, a Letter of Authorization when your filing needs one, current change notifications, the batch COA, and a clear manufacturing-site statement.
What Should We Do If a COA Omits a Result?
Treat omitted numerical results, unclear method references, or generic pass statements as incomplete evidence. Request clarification and documentation before approving the batch for formulation work.
